Skip to main content
Premium Trial:

Request an Annual Quote

National Human Genome Center of Shanghai Sees Company Born

NEW YORK, Sept. 4 - Shanghai IgCon Therapeutics, a joint venture of Genetastix and the South Gene Technology Company, got the official green light to begin operations from the Shanghai municipal government, the companies said today.


Shanghai IgCon Therapeutics, established last November, will focus on pre-clinical and clinical development of human therapeutic antibodies for the Chinese and Asian markets, according to the company.


The South Gene Technology Company is the commercial arm of the National Human Genome Center of Shanghai, which was established in 1998.


Genetastix is based in San Jose, Calif.


For further information, see the press release.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.